Jazz Pharmaceuticals plc (JAZZ) Earnings
Jazz Pharmaceuticals plc is expected to report next earnings on August 4, 2026 (in NaN days), with a consensus EPS estimate of $6.18. JAZZ has beaten EPS estimates in 7 of its last 12 reported quarters (average surprise +21.5% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 5, 2026 | $4.67 | $6.34 | +35.8% | $1.1B | +9.2% |
| Feb 24, 2026 | $6.62 | $6.64 | +0.3% | $1.2B | +24.5% |
| Nov 5, 2025 | $5.95 | $8.13 | +36.6% | $1.1B | +1.3% |
| Feb 25, 2025 | $5.83 | $6.60 | +13.2% | $1.1B | +10.5% |
| Jul 31, 2024 | $4.68 | $5.30 | +13.2% | $1.0B | -1.3% |
| May 1, 2024 | $4.14 | $2.68 | -35.3% | $902M | -5.4% |
| Feb 28, 2024 | $5.26 | $5.02 | -4.6% | $1.0B | +5.7% |
| Mar 1, 2023 | $0.51 | $-0.07 | -113.7% | $972M | +8.6% |
| Nov 9, 2022 | $4.72 | $5.17 | +9.5% | $941M | +0.1% |
| Aug 3, 2022 | $4.20 | $4.30 | +2.4% | $933M | +3.4% |
| May 4, 2022 | $3.75 | $3.73 | -0.5% | $814M | -4.5% |
| Mar 1, 2022 | $3.71 | $4.21 | +13.5% | $897M | +3.8% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 5, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
### Commercial Execution: Built on record year in 2025, first quarter had highest ever total revenues of $1.1 billion, +19% YOY. Commercial teams had double-digit growth across promoted brands, with strong contributions from ongoing launches. ### R&D Progress: Urgently advancing Zyhera for HER2-positive first-line locally advanced or metastatic GEA, FDA accepted SBLA, granted priority review. Pipeline progress with multiple ongoing registrations, early stage trials, and early development of neuroscience and epilepsy assets. ### Operational Start: Cash flow over $400 million in Q1, non-GAAP adjusted EPS $6.34. Financial strength enables investment in commercial portfolio, pipeline, and business development in rare disease.
Guidance
### Revenue Guidance: Reaffirming full-year 2026 revenue guidance of $4.25 to $4.5 billion. ### Sleep Business: Anticipate competitive dynamics in second half, including high-sodium generics gaining volume and potential daytime weight-promoting agents entering narcolepsy market. ### Zepzelka: Expect first-line maintenance adoption to grow, second-line use to decrease due to competition and fewer Zepzelka-naive patients. ### FX Impact: Significant devaluation of U.S. dollar contributed ~1.5 percentage points to worldwide revenue growth in Q1.
Segment performance
### Sleep: ZyWave net product sales increased 18% to $408 million in Q1 2026. There were approximately 425 net patient adds, and now ~16,600 active patients. Field teams expand markets, and JazzCare support services are differentiators. Revenue contribution: significant, driven by strong demand. ### Epilepsy: Epidiolex net product sales increased 15% to $250 million in Q1 2026, driven by 16% volume growth. Focus on adult patient population, long-term care setting, and nurse navigator program. Revenue contribution: important, with growth in underlying demand. ### Oncology: - Zahira: Generated net product sales of $13 million in Q1 2026. Positive feedback from biliary tract cancer physicians, expanding into new accounts. Revenue contribution: part of oncology portfolio growth. - GEA launch preparations: Zyhera has potential to be preferred HER2-directed therapy for HER2-positive first-line metastatic GEA. Data from Horizon GEA trial shows improved outcomes. Revenue contribution: potential significant with approval. - Medeso: Generated $41 million in net product sales in Q1 2026. Strong early performance post-launch in August 2025, treating ~500 patients. Revenue contribution: early but growing. - Zepzelka: Net product sales increased 60% to $101 million in Q1 2026, driven by strong uptake in frontline maintenance setting. Revenue contribution: significant growth from first-line maintenance adoption.
Risks & headwinds
### Forward-Looking Statements: Include risks and uncertainties that could cause actual results to differ materially. Risks described in press release and Form 10-K. ### Competitive Risks: In sleep business, potential competitive pressure from generics and new agents. In oncology, competition could impact Zepzelka's second-line use. ### Regulatory Risks: Uncertainties in regulatory approval timelines and processes for pipeline assets.
Analyst Q&A
Q: Question on Zany Datamab for breast cancer regarding sequencing agents.
A: Rob mentioned trial 303 will evaluate Zanidatamab vs standard of care in post and HER2 setting to inform decisions.
Q: Question on size of patient population for Medezo and M&A thinking.
A: Sam said Medezo has $41M in Q1, $500M peak opportunity in US, patient population estimates, and Renee said BD active, focused on rare disease, looking at licensing, structured deals, M&A.
Q: Question on epilepsy area focus and cannibalization.
A: Renee said epilepsy is focus, significant unmet need, Epidiolex has long durability, room for new mechanisms, will continue to invest.
Q: Question on Modazo moving to first-line treatment.
A: Sam said action study could expand market by more patients and longer duration of treatment, Rob mentioned event-driven trial with interim and final analysis.
Q: Question on Epidiolex OUS and Rylase.
A: Mark Goodman was told Epidiolex OUS had strong growth, ~2/3 volume, ~1/3 FX and UK VPag adjustment, Rylase had $104M, 10% growth, COG impact realized.
Q: Question on second half dynamics for oxidates and competitive pressure.
A: Jordan Becker was told ZyWave had 18% growth, volume growth, first quarter had net price pickup, competitive landscape viewed as complementary with orexins.
Q: Question on Epidiolex adult and long-term care setting and study.
A: Sam said Epidiolex has adult segment and long-term care focus, invested in teams and tools, Rob mentioned focal onset seizure study with data to be published.
Q: Question on Zepzelka IP and life beyond 2029.
A: Renee said strong patent estate for Zepzelka, multiple patents out to 2040, pursuing new patents, and suit against filers with stay of approval.
Q: Question on ZyWave growth and MFN.
A: Jason Gerberry was told ZyWave had 18% growth, first quarter had net price pickup, MFN considerations uncertain.
Q: Question on ZyWave headwinds and Medezo action trial.
A: Amy Fadia was told ZyWave has strong momentum, continued support, and Rob said Medezo action trial is OS-based with interim and final analysis.
Q: Question on NCCN guideline for Zyhera and breast cancer opportunity.
A: Rob said NCCN guidelines will be updated with manuscript, Zyhera data supports category one inclusion, breast cancer opportunity significant.